AHA 2019 – The Medicines Company reaches for the stars
Two more Orion trials have hit neatly and cleanly, and now success will be largely down to pricing.
Novo goes small with big Dicerna deal
Novo Nordisk takes its first step into RNA with a broad cardio-metabolic deal with Dicerna, the biggest sealed by the US biotech to date.
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Threats to Spinraza are mounting, but Biogen still has cards to play
Competition is looming from Novartis and Roche but the latest results from Spinraza show that Biogen still has a strong case to make for the SMA therapy.
Upcoming events – Novartis and Miragen hope for heartening data
Upcoming data could help Novartis broaden the reach of its heart failure drug Entresto, while Miragen awaits a key test of its microRNA approach.
AAN 2019 – Roche confirms its place in spinal muscular atrophy
A slew of data on spinal muscular atrophy projects over the weekend shows that this tiny market is set for some big competition, with Novartis, Roche and Biogen jostling…
Alnylam swaps Regeneron for Sanofi
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
Readouts approach for biggest Huntington’s hopes
Upcoming data from Roche/Ionis and Wave Life Sciences will be an important test of potentially disease-modifying candidates.
Alnylam touts givosiran win despite toxicity fears
Alnylam looks likely to get approval for its second RNAi candidate, givosiran. But toxicity issues have tainted the Envision trial win.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.